Trizoron-60 MR Tablet
Trimetazidine 60 mg (Modified Release)
| Composition | Trimetazidine 60 mg (Modified Release) |
|---|---|
| Dosage Form | Tablet |
| Pack Type | Box |
| Pack Size | 10 x 10 (Blister) |
| MRP | ₹ 1950 |
| Therapy | Cardiac + Diabetic — Metabolic anti-anginal (modified release) |
| Storage | Store below 25°C. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Trizoron-60 MR Tablet
Trizoron-60 MR Tablet provides Trimetazidine 60 mg in modified-release form for stronger metabolic anti-anginal effect with twice-daily dosing.
Indicated for chronic stable angina inadequately controlled by first-line agents.
Camrut Healthcare manufactures Trizoron-60 MR under WHO-GMP conditions for PCD pharma franchise across India.
Indications
- Chronic stable angina (refractory)
- Add-on anti-anginal therapy
- Angina with normal HR/BP on first-line therapy
Mechanism of Action
Trimetazidine inhibits 3-KAT, shifting cardiac metabolism from fatty-acid to glucose oxidation — more O2-efficient ATP production in ischaemic myocardium without affecting HR, BP or contractility.
Dosage & Administration
['1 tablet twice daily with meals', 'Swallow whole', "Avoid in Parkinson's disease"]
Side Effects
['GI upset', 'Headache', 'Mild dizziness', 'Parkinsonian symptoms (rare, reversible)']
Contraindications & Precautions
["Parkinson's disease", 'Parkinsonian symptoms', 'Severe renal impairment']
Storage
Store below 25°C.
Trizoron-60 MR Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
q
a
q
a
q
a
q
a
q
a
Related Products
- Trizoron-20 Tablet — Trimetazidine 20 mg
- Trizoron-35 MR Tablet — Trimetazidine 35 mg (Modified Release)
- Trizoron-80 OD Capsule — Trimetazidine 80 mg (Controlled Release Capsule)